The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2021 | CAR-T trials to watch in China
Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, shares key Chinese CAR-T clinical trials to look out for. Two different clinical trials investigating CD19 CAR T-cells for non-Hodgkin lymphoma are almost completed, and approval is expected soon in China. Additionally, clinical trials studying BCMA CAR T-cell therapy for multiple myeloma are also making good progress. Lastly, Prof. Wang highlights clinical trials evaluating CD19 CAR T-cells for relapsed/refractory acute lymphoblastic leukemia (ALL), particularly for adults. This interview took place during the 3rd European CAR T-cell Meeting.
Disclosures
Advisor for Abbvie
